Introduction
============

Pre-operative anxiety is a commonly encountered unpleasant and stressful state prior to surgery, which may negatively affect treatment outcomes, lead to an increased demand for anesthetics during surgery and enhance vulnerability to infection ([@b1-etm-0-0-8040]). Previous studies have proved that high pre-operative anxiety predicts increased intra-operative sedative requirements ([@b2-etm-0-0-8040]). Effective intra-operative sedation is required to relieve anxiety, as well as for patient cooperation and satisfaction with the surgery.

Butorphanol is a synthetic opioid with partial agonist action at the µ-opioid and κ-opioid receptors ([@b3-etm-0-0-8040]); it has analgesic and sedative effects and only few side effects, low addiction potential and low toxicity ([@b4-etm-0-0-8040]). The World Health Organization guidelines also recommend the use of butorphanol as an adjunctive anesthetic for intra-operative sedation and post-operative pain relief ([@b5-etm-0-0-8040]).

Several studies have reported on sedative drugs commonly used during surgery ([@b2-etm-0-0-8040],[@b6-etm-0-0-8040],[@b7-etm-0-0-8040]). However, few studies have been performed on sedation with butorphanol in patients with pre-operative anxiety. Furthermore, a formula to predict the precise butorphanol requirement to maintain patients with a high pre-operative anxiety score in an adequate sedative state has remained to be determined.

In the present study, patients who were scheduled for orthopedic procedures under regional anesthesia were selected and prior to the surgery, their pre-operative anxiety score was evaluated by using the Amsterdam pre-operative anxiety and information scale (APAIS). It was hypothesized that there is an association between the APAIS score and the duration of reaching adequate sedation, which can potentially be used to predict the requirement of butorphanol.

Patients and methods
====================

### Subjects

The inclusion criteria were as follows: i) Chinese male or female patients aged 18--75 years; ii) American Society of Anaesthesiologists physical status I or II ([@b8-etm-0-0-8040]); iii) scheduled for elective lower limb orthopedic procedures under regional anesthesia at Shengjing Hospital of China Medical University (Shenyang, China) between March 2018 and March 2019. The exclusion criteria were as follows: i) Central nervous system disease; ii) cardiovascular disease; iii) autonomic nervous system disease; iv) long-term use of analgesic, sedative or anti-anxiety drugs; vi) psychosis or a language communication disorder; vii) patient did not provide informed consent.

Following assessment of 155 patients for eligibility, 13 patients were excluded based on the above-mentioned criteria. Finally, 142 patients were enrolled as eligible subjects. After evaluating the patients\' pre-operative anxiety score by using the APAIS scale ([@b9-etm-0-0-8040]--[@b12-etm-0-0-8040]), as well as a computer-generated sequence of random numbers and a sealed-envelope technique, 75 patients in the high pre-operative anxiety group (pre-operative anxiety score \>10) were randomized to receive one of the two treatments (high-anxiety butorphanol group, n=38; high-anxiety 0.9% saline group, n=37) and 67 patients in the low pre-operative anxiety group (pre-operative anxiety score ≤10) were also randomized to receive one of the two treatments (low-anxiety butorphanol group, n=34; low-anxiety 0.9% saline group, n=33). Following completion of the study, 5 patients in the high pre-operative anxiety group were excluded from the study, comprising 2 patients who did not reach a Ramsay Sedation Score (RSS) of 4 during the operation ([@b13-etm-0-0-8040]), 2 patients who received rescue analgesic and 1 patient with incomplete data. Furthermore, 6 patients in the low pre-operative anxiety group were excluded from the study, comprising 2 patients with incomplete data, 1 patient with inadequate anesthesia and 3 patients who received rescue analgesic. Therefore, the data from 36 patients in the high-anxiety butorphanol group and 34 patients in the high-anxiety 0.9% saline group were analyzed in the present study. Furthermore, the data from 32 patients in the low-anxiety butorphanol group and 29 patients in the low-anxiety 0.9% saline group were analyzed in the present study ([Fig. 1](#f1-etm-0-0-8040){ref-type="fig"}).

### Study design

This study was approved by the Human Research Ethical Committee of Shengjing Hospital (Shenyang, China; IRB registration no. 2018PS254K) and written informed consent was obtained from all subjects participating in the trial. The trial was registered prior to patient enrollment at [clinicaltrials.gov](clinicaltrials.gov) (no. NCT03429179; principal investigator, Bijia Song; date of registration, 20.01.2018).

In the present study, the APAIS was used by an experimental assistant to evaluate the degree of pre-operative anxiety of patients enrolled in the study prior to administration of pre-medication. According to the total anxiety score on the APAIS, patients were divided into a high pre-operative anxiety group (pre-operative anxiety score \>10) and a low pre-operative anxiety group (pre-operative anxiety score ≤10). Although a previous study have stated that it was acceptable to not provide sedation for this type of lower-limb surgery under local anesthesia ([@b14-etm-0-0-8040]), patients enrolled into the present study were exhibiting pre-operative anxiety and it was considered ethical to provide sedation. Preliminary experiments performed by our group indicated no statistically significant differences in RSS after pre-operative intramuscular injection of low-dose midazolam for patients with different anxiety levels, which was confirmed by statisticians ([@b15-etm-0-0-8040]). Thus, intramuscular midazolam (0.05 mg/kg) as a pre-medication was administered to patients 60 min prior to transfer to the operating room. All patients were routinely prepared according to the requirements of regional anesthesia. Upon arrival in the operating room, standard monitoring, including an electrocardiogram, non-invasive blood pressure (NIBP) and peripheral oxygen saturation (SpO~2~), were applied. Regional anesthesia was then implemented through the L2-3 or L3-4 intervertebral space and 0.5% bupivacaine was injected into the subarachnoid cavity according to the age and weight of the patients until the block plane reached T8-T10. In the high-anxiety butorphanol group and low-anxiety butorphanol group, patients received an intravenous (i.v.) loading dose of 15 µg/kg butorphanol 5 min prior to the beginning of the surgery, followed by infusion of 7.5 µg/kg/h butorphanol and the infusion was stopped when the RSS reached 4. The high-anxiety 0.9% saline group and the low-anxiety 0.9% saline group received an infusion of the same volume of 0.9% saline. Ramosetron (0.3 mg) was administered prophylactically at the end of the surgery. The anesthesiologist connected the i.v. microcomputer-controlled drug-infusion devices to the patients (Kelijianyuan Med. Co.). The study was double-blinded for all of the researchers, physicians who collected the data, the nurses and the staff who prepared the medications. Each device syringe was filled with butorphanol or 0.9% saline from similar ampoules to the same volume. The timeline of the experimental procedure is provided in [Fig. 2](#f2-etm-0-0-8040){ref-type="fig"}.

### Experimental data collection

NIBP, mean arterial pressure (MAP) and heart rate (HR) were recorded 10 min after entering the operating room (baseline, T~0~), and at 5 min (T~1~), 10 min (T~2~), 15 min (T~3~) and 30 min (T~4~) after the commencment of i.v. butorphanol infusion of. Hypotension (MAP \<70 mmHg) was treated with fluid boluses and 6 mg i.v. boluses of ephedrine, while bradycardia (HR\<50 bpm) was treated with 0.6 mg i.v. atropine. Respiratory depression was defined as a respiratory rate of \<8 breaths/min or an SpO~2~ of \<90% on room air. Patients were given supplemental O~2~ via face mask at 6 l/min if the SpO~2~ decreased \<90%. The RSS in the four groups was recorded at 10 min after entering the operation room and at 5, 10, 15 and 30 min after infusion of butorphanol or 0.9% saline, and the duration for the RSS to reach 4 in the high-anxiety butorphanol group and the low-anxiety butorphanol group was also recorded. In the post-operative period, pain scores were assessed on the visual analogue scale (VAS) ([@b16-etm-0-0-8040]) every hour up to 6 h and then every 2 h up to 24 h. Patients were given flurbiprofen axetil 50 mg as a rescue analgesic and then excluded from the analysis. Adverse events, including nausea/vomiting, dizziness, bradycardia and respiratory depression were recorded at the same time-points as the VAS scores and treated accordingly.

### Evaluation of pre-operative anxiety

The APAIS is a questionnaire to assess patients\' pre-operative anxiety score, which was developed in 1996 by the Dutch clinician Moerman ([@b9-etm-0-0-8040]). The APAIS comprises 6 items rated on a five-point Likert scale, which includes two scales: Anxiety (items 1, 2, 4 and 5) and requirement for information (items 3 and 6) ([@b10-etm-0-0-8040],[@b11-etm-0-0-8040]). The maximal total APAIS score is 30; this is comprised of a maximum score expressing the patient\'s requirement for information of 10 and a maximal score of the two items concerning anxiety regarding anesthesia and surgery of 10 each, resulting in a maximal score of 20 for total anxiety (APAIS-A-T). In the present study, APAIS-A-T \>10 was used as a cut-off to define patients with high anxiety, with a higher score indicating a higher level of anxiety ([@b12-etm-0-0-8040]).

### Evaluation of sedation

The depth of sedation was determined based on the RSS scale ([@b13-etm-0-0-8040]), as follows: 1, Anxious and agitated or restless or both; 2, cooperative, orientated and tranquil; 3, responds to commands only; 4, brisk response to a light glabellar tap or auditory stimulus; 5, sluggish response to a light glabellar tap or auditory stimulus; and 6, no response to a light glabellar tap or auditory stimulus. Patients with a sedation score equal to 4 were considered to have adequate sedation.

### Evaluation of patient satisfaction

Patient satisfaction was recorded on 5 levels: a) Agreeable experience; b) neither pleasant nor unpleasant; c) slightly uncomfortable; d) disagreeable experience; e) traumatic experience.

### Statistical analysis

SPSS 20.0 statistical software (IBM Corp.) was used for data analysis. Continuous variables are expressed as the mean ± standard deviation and the Chi-squared test was used to analyse differences in demographic data, post-operative side effects and patient satisfaction between groups. Comparisons between two groups were performed by using an independent-samples Student\'s t-test. One-way analysis of variance (ANOVA) followed by Bonferroni correction was used for multiple comparisons and Welch\'s ANOVA followed by Tamhane\'s T2 post-hoc pairwise comparison was used for multiple groups which did not meet the Levene\'s test criteria. Linear association analysis was performed between the APAIS score and duration of RSS reaching 4 to calculate an r^2^ value. P\<0.05 was considered to indicate statistical significance.

Results
=======

### Patient characteristics

The patient characteristics are provided in [Table I](#tI-etm-0-0-8040){ref-type="table"}. There were no significant differences among the study groups regarding demographic characteristics, type of surgery or duration of surgery.

### Comparison of the RSS among the different groups

The RSS score of the different groups at various time-points is provided in [Table II](#tII-etm-0-0-8040){ref-type="table"}. Of note, there was no significant difference in RSS at 10 min after entering the operating room among the four groups (P\>0.05). The sedation scores of the high-anxiety 0.9% saline group were lower than those of the high-anxiety butorphanol group at each time-point after infusion (P\<0.05). There were also significant differences between the high-anxiety butorphanol group and the low-anxiety butorphanol group at each time-point after infusion (P\<0.05).

### Association between the APAIS score and duration of RSS reaching 4

As presented in [Fig. 3](#f3-etm-0-0-8040){ref-type="fig"}, an approximately linear correlation between the APAIS score and duration of RSS reaching 4 was observed. Linear regression analysis revealed an r^2^-value of 0.887, suggesting that 88.7% of the variation in the time taken for the RSS to reach 4 may be accounted for by the APAIS score (P\<0.0001). The regression equation was determined as follows: Duration of reaching adequate sedation (min)=(1.075 × APAIS score) + 2.081. According to the butorphanol infusion method applied in the present study, the formula to determine the required dose was as follows: Precise dose of butorphanol (µg/kg)=15.26 + (0.14 × APAIS score).

### Comparison of HR and MAP among the different groups

The HR and MAP in the different groups at each time-point are provided in [Table III](#tIII-etm-0-0-8040){ref-type="table"}. In the high-anxiety butorphanol group and low-anxiety butorphanol group, the MAP at each time-point was significantly lower than that at the respective previous time-point in the same group (P\<0.05). However, no significant differences were obtained in the high-anxiety 0.9% saline group and low-anxiety 0.9% saline group with this regard (P\>0.05). The MAP at each time point in the high-anxiety 0.9% saline group was higher compared with that in the other three groups. Furthermore, the HR at T0 in the high-anxiety butorphanol group and high-anxiety 0.9% saline group were higher compared with that in the low-anxiety butorphanol group, though there was no significant difference between the low-anxiety 0.9% saline and the low-anxiety butorphanol groups. The HR value in the high-anxiety 0.9% saline group remained at a high level during the operation. There was no difference in SpO~2~ among the four groups during the course of the study (data not shown).

### Post-operative recovery

The VAS scores were significantly lower in the butorphanol groups (high-anxiety butorphanol group and low-anxiety butorphanol group) as compared with those in the 0.9% saline groups (high-anxiety 0.9% saline group and low-anxiety 0.9% saline group) throughout the the first 24 h post operation (P\<0.05; [Table IV](#tIV-etm-0-0-8040){ref-type="table"}). The differences in adverse events (nausea/vomiting, dizziness, bradycardia and respiratory depression) were statistically insignificant among the four groups ([Table IV](#tIV-etm-0-0-8040){ref-type="table"}). However, regarding post-operative patient satisfaction, the rating 'agreeable experience' was significantly more frequently given by the group receiving intra-operative sedation (P=0.032), while the saline group more frequently provided the rating 'disagreeable experience' (P=0.005) compared with the respective other group ([Table V](#tV-etm-0-0-8040){ref-type="table"}).

Discussion
==========

The results of the present study indicated that the requirement of butorphanol for conscious sedation was correlated with the level of pre-operative anxiety in patients receiving lower-limb orthopedic surgery under regional anesthesia. The duration of reaching an adequate sedative state increased approximately linearly with the increase of the APAIS score, which may suggest that for a higher anxiety score, more butorphanol should be used. Previous studies have also reported a correlation between different levels of anxiety and sedative or anesthetic requirement when conscious sedation or anesthesia is used ([@b2-etm-0-0-8040],[@b17-etm-0-0-8040],[@b18-etm-0-0-8040]), which was consistent with the results of the present study.

In the present study, APAIS, as a well-established measuring scale, was used to evaluate the level of the patients\' pre-operative anxiety, which was also used in previous studies ([@b19-etm-0-0-8040],[@b20-etm-0-0-8040]), and the clinical scoring method used to measure the level of patient sedation was the commonly used RSS scale ([@b21-etm-0-0-8040]). A sedative state with an RSS of 3 or 4 was considered as an adequate level of sedation ([@b22-etm-0-0-8040]). Therefore, in the present study, the time taken for the RSS to reach 4 was defined as the endpoints of i.v. butorphanol infusion (i.e. the time infusion was terminated).

Lower-limb orthopedic surgery is frequently performed with regional anesthesia ([@b23-etm-0-0-8040]). Despite several advantages, those surgeries are associated with discomfort and worry for the patients. Furthermore, lower-limb orthopedic surgery usually requires to be performed under the tourniquet to achieve a clear operation field. However, application of a tourniquet is a non-physiological process, resulting in an irritable state, local sense of pressure and higher blood pressure after a certain time. Becher *et al* ([@b24-etm-0-0-8040]) reported that patients were prone to depression and anxiety after orthopedic injuries, which was also in accordance with our experience at our institution. Stress factors in the operating room and ineffective or patchy blocks may aggravate nervosity and anxiety in patients under regional anesthesia. Thus, sufficient sedation and cooperation of the patient are of great importance.

Procedural sedation, known as monitored anesthesia care, includes methods including a single-dose, intermittent or continuous infusion. However, the different responses of patients with different levels of pre-operative anxiety to sedative drugs may result in ineffective or deep sedation ([@b2-etm-0-0-8040]). In the present study, to better explore the sedative requirements of patients with different pre-operative anxiety scores, butorphanol was administered with a loading dose followed by a maintenance dose. A previous study also reported that continuous i.v. infusion of butorphanol was able to maintain plasma butorphanol concentrations within a stable range, resulting in effective analgesia, and the side effects were reduced during the infusion compared with a single injection of butorphanol ([@b25-etm-0-0-8040]). The total safe dose of butorphanol that may be given i.v. is 20--40 µg/kg ([@b26-etm-0-0-8040]). According to the administration method in the present study, the total dose of butorphanol may be guaranteed to be in the safe range when the duration of the operation is ≤3.5 h. In the present study, the longest duration of surgery did not exceed 3.5 h and the total dose of butorphanol was still in the safe range.

Sinha *et al* ([@b7-etm-0-0-8040]) reported that butorphanol provided satisfactory sedation, and in the present study, the RSS in patients with high pre-operative anxiety in the butorphanol group was higher than that in patients with high pre-operative anxiety in the 0.9% saline group at each time-point after infusion. Furthermore, a linear correlation between the duration for the RSS to reach 4 and the APAIS score of patients in the butorphanol groups was determined, and the butorphanol infusion method applied in the present study was as follows: The total dose of butorphanol was administered as a loading dose of 15 µg/kg butorphanol, followed by infusion of 7.5 µg/kg/h. After substituting the linear regression equation derived from the correlation graph into that for the butorphanol infusion method, the following formula was obtained: Precise dose of butorphanol (µg/kg)=15.26 + (0.14 × APAIS score).

Pre-operative anxiety was also reported to cause fluctuation of hemodynamics and damage to sleep quality, which may be potentially harmful to patients; however, an adequate sedative state in patients may reduce hemodynamic changes and raise the level of patients\' satisfaction ([@b27-etm-0-0-8040]). In the present study, the hemodynamics were kept lower during the operation in MAP and HR in patients with high pre-operative anxiety in the butorphanol group than in patients with high pre-operative anxiety in the 0.9% saline group. The level of patient satisfaction with conscious i.v. sedation was between agreeable and neither pleasant nor unpleasant for 92.6% of patients and slightly uncomfortable for 7.4%, which was better than in the patients in the 0.9% saline groups. The side effects were similar among patients, regardless of the level of pre-operative anxiety. Although the incidence of nausea/vomiting and dizziness in patients with high pre-operative anxiety in the butorphanol group was higher than that in the other three groups, there were still no significant differences among the four groups. None of the patients had respiratory depression or bradycardia in the first 24 h post-operation.

Sinha *et al* ([@b7-etm-0-0-8040]) also demonstrated that butorphanol decreased the post-operative analgesic requirement. Similar to their results, the present study indicated that the VAS scores were significantly lower in the butorphanol groups as compared with those in the 0.9% saline groups throughout the first 24 h post-operation.

The present study has certain limitations that are worth mentioning. First, the RSS scale and APAIS used in the present study are authoritative scales, while the method used to measure the level of patient sedation and pre-operative anxiety were based on the subjective observation of the investigator, leading to a lack of objectivity of data to a certain extent. Furthermore, the proposed formula requires further improvement to determine which way of infusion should be used to rapidly achieve an adequate sedative state. Finally, after application of sedative drugs, there were still two patients with a high pre-operative anxiety score in the butorphanol group who did not reach RSS 4 throughout the operation, which may suggest that the infusion method applied in the present study does not apply to all types of patient.

In conclusion, butorphanol did not only provide an effective sedative and analgesic effect without a significant increase in adverse effects, including nausea, vomiting, bradycardia or respiratory depression, but also provided stable hemodynamic changes during the surgery and higher post-operative satisfaction for patients with pre-operative anxiety. The formula proposed was as follows: Precise dose of butorphanol (µg/kg)=15.26 + (0.14 × APAIS score; adherence to this formula may provide an improvement for patients who exhibit a high level of pre-operative anxiety. If patients with a higher pre-operative anxiety score do not achieve adequate sedation within the calculated total dose, combined use of other sedative drugs should be considered.
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APAIS

:   Amsterdam pre-operative anxiety and information scale

RSS

:   Ramsay sedation score
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:   non-invasive blood pressure
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:   peripheral oxygen saturation
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:   mean arterial pressure

HR

:   heart rate

VAS

:   visual analogue scale
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###### 

Patient characteristics.

                                High pre-operative anxiety group   Low pre-operative anxiety group                           
  ----------------------------- ---------------------------------- --------------------------------- ----------- ----------- -------
  Sex                                                                                                                        0.888
    Male                        17 (47.2)                          14 (41.2)                         13 (40.6)   11 (37.9)   
    Female                      19 (52.8)                          20 (58.8)                         19 (59.4)   18 (62.1)   
  Age (years)                   47.1±16.8                          47.3±16.0                         41.5±14.2   41.0±12.3   0.172
  Weight (kg)                   65.8±3.0                           68.6±10.6                         69.8±8.3    66.0±4.1    0.069
  Duration of surgery (min)     83.3±15.8                          84.0±16.5                         85.2±18.4   86.5±16.4   0.877
  Type of surgery                                                                                                            0.283
    Repair of ligament injury   15 (41.7)                          17 (50)                           11 (34.4)   9 (31.1)    
    Repair of meniscus injury   11 (30.6)                          8 (23.5)                          10 (31.3)   15 (51.7)   
    Other                       10 (27.8)                          9 (26.5)                          11 (34.4)   5 (17.2)    

Values are expressed as the mean ± standard deviation or as n (%).

###### 

Ramsay Sedation Score.

  Group                             T0         T1                                                                                                    T2                                                                                                    T3                                                                                                    T4
  --------------------------------- ---------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  High pre-operative anxiety                                                                                                                                                                                                                                                                                                                                     
  butorphanol group                 1.42±0.5   1.92±0.6^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"}^                                                2.22±0.5^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"}^                                                2.42±0.5^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"}^                                                3.31±1.0^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"}^
  0.9% saline group                 1.41±0.5   1.47±0.5^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^   1.53±0.5^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^   1.65±0.6^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^   1.82±0.6^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^
  Low pre-operative anxiety group                                                                                                                                                                                                                                                                                                                                
  butorphanol group                 1.53±0.5   2.34±0.5^[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^                                                2.91±0.8^[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^                                                3.47±0.8^[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^                                                4.0±0.0^[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^
  0.9% saline group                 1.52±0.4   1.55±0.5^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^   1.66±0.7^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^   1.83±0.7^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^   1.97±0.5^[a](#tfn2-etm-0-0-8040){ref-type="table-fn"},[b](#tfn3-etm-0-0-8040){ref-type="table-fn"}^
  P-value                           0.665      \<0.001                                                                                               \<0.001                                                                                               \<0.001                                                                                               \<0.001

P\<0.05 vs. Low-anxiety butorphanol group

P\<0.05 vs. High-anxiety butorphanol group. Values are expressed as the mean ± standard deviation. T0, 10 min after entering the operating room; T1, 5 min after intravenous infusing butorphanol; T2, 10 min after intravenous infusing butorphanol; T3, 15 mins after intravenous infusing butorphanol 15 min; T4, 30 min after intravenous infusing butorphanol.

###### 

Comparison of HR and MAP among different groups.

  A, HR                                                                                                                                                                                                                                                                                  
  ---------------------------------- --------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------
  High pre-operative anxiety group   70                                                                                                                                                                                                                                                  
    Butorphanol group                36              88.1±9.3^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   73.4±8.2^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   70.4±9.2^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   68.1±7.9^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   66.3±7.7^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^
    0.9% saline group                34              89.8±8.4^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   88.4±5.1^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   88.1±5.6^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   87.0±7.9^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   86.2±6.7^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^
  Low pre-operative anxiety group    61                                                                                                                                                                                                                                                  
    Butorphanol group                32              74.0±7.7                                                 71.7±6.6^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   69.8±7.3^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   68.3±6.2                                                 66.1±5.8
    0.9% saline group                29              73.1±6.4                                                 72.1±6.4                                                 71.1±7.5                                                 70.7±5.8                                                 70.0±5.0
                                                                                                                                                                                                                                                                                         
  **B, MAP**                                                                                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                                         
  **Group**                          **Cases (n)**   **T0**                                                   **T1**                                                   **T2**                                                   **T3**                                                   **T4**
                                                                                                                                                                                                                                                                                         
  High pre-operative anxiety group   70                                                                                                                                                                                                                                                  
    Butorphanol group                36              96.1±3.9^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   88.3±3.2^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   84.8±4.0^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   82.7±3.6^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   80.9±3.6^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^
    0.9% saline group                34              97.9±5.7^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   97.1±4.2^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   96.4±3.4^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   95.7±3.3^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   95.0±3.6^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^
  Low pre-operative anxiety group    61                                                                                                                                                                                                                                                  
    Butorphanol group                32              89.3±4.8                                                 86.9±3.9^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   83.9±5.2^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   81.9±2.8^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^   80.5±2.9^[b](#tfn5-etm-0-0-8040){ref-type="table-fn"}^
    0.9% saline group                29              88.5±5.2                                                 88.2±4.8                                                 87.3±3.6^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   86.8±2.8^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^   86.1±2.8^[a](#tfn4-etm-0-0-8040){ref-type="table-fn"}^

P\<0.05 vs. low-anxiety butorphanol group.

P\<0.05 vs. the previous time-point. Values are expressed as the mean ± standard deviation. HR, heart rate; MAP, mean arterial pressure; T0, 10 min after entering the operating room; T1, 5 min after intravenous infusing butorphanol; T2, 10 min after intravenous infusing butorphanol; T3, 15 mins after intravenous infusing butorphanol 15 min; T4, 30 min after intravenous infusing butorphanol.

###### 

Post-operative parameters in the first 24 h after operation.

  A, Adverse events                                                                                           
  --------------------------------- ------------------------ ------------------------ ------------- --------- -------
  Nausea and vomiting               7 (19.4)                 6 (17.6)                 3 (9.4)       1 (3.4)   0.196
  Dizziness                         7 (19.4)                 3 (8.8)                  5 (15.6)      2 (6.9)   0.391
  Respiratory depression            0 (0)                    0 (0)                    0 (0)         0 (0)     --
  Bradycardia                       0 (0)                    0 (0)                    0 (0)         0 (0)     --
                                                                                                              
  **B, Post-operative VAS score**                                                                             
                                                                                                              
  **Time-point (h)**                **Butorphanol groups**   **0.9% Saline groups**   **P-value**             
                                                                                                              
  1                                 0.90±0.7                   2.79±0.8                 \<0.001               
  2                                 1.16±0.6                   3.22±0.7                 \<0.001               
  4                                 1.44±0.5                   3.62±0.5                 \<0.001               
  6                                 1.79±0.4                   3.76±0.4                 \<0.001               
  12                                2.62±0.6                   4.29±0.8                 \<0.001               
  24                                3.28±0.6                   5.13±0.6                 \<0.001               

Values are expressed as the mean ± standard deviation. Butorphanol groups: High-anxiety butorphanol group and low-anxiety butorphanol group; 0.9% Saline groups: High-anxiety 0.9% saline group and low-anxiety 0.9% saline group. VAS, visual analogue scale.

###### 

Post-operative patient satisfaction.

  Rating                            Butorphanol groups   0.9% Saline groups   P-value
  --------------------------------- -------------------- -------------------- ---------
  Agreeable experience              44 (64.7)            29 (46)              0.032
  Neither pleasant nor unpleasant   19 (27.9)            18 (28.6)            0.936
  Slightly uncomfortable            5 (7.4)              9 (14.3)             0.199
  Disagreeable experience           0 (0)                7 (11.1)             0.005
  Traumatic experience              0 (0)                0 (0)                --

Values are expressed as the mean ± standard deviation. Butorphanol groups: High-anxiety butorphanol group and low-anxiety butorphanol group; 0.9% saline groups: High-anxiety 0.9% saline group and low-anxiety 0.9% saline group.
